IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by GTS Securities LLC

GTS Securities LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 55.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,417 shares of the medical research company's stock after selling 6,708 shares during the quarter. GTS Securities LLC's holdings in IQVIA were worth $1,064,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Norges Bank purchased a new position in shares of IQVIA during the 4th quarter valued at about $336,041,000. Raymond James Financial Inc. acquired a new stake in IQVIA during the fourth quarter worth about $236,120,000. American Century Companies Inc. raised its position in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after acquiring an additional 905,960 shares in the last quarter. Invesco Ltd. lifted its holdings in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, Canada Pension Plan Investment Board lifted its holdings in IQVIA by 20.0% in the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after acquiring an additional 712,958 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on IQV shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Robert W. Baird decreased their price objective on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Finally, HSBC cut IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Price Performance

NYSE IQV traded down $1.95 during trading hours on Wednesday, hitting $138.59. 1,601,507 shares of the company's stock traded hands, compared to its average volume of 1,567,567. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The company has a market capitalization of $23.98 billion, a PE ratio of 18.48, a PEG ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm's 50-day moving average is $153.47 and its 200-day moving average is $182.26.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the prior year, the company earned $2.54 EPS. IQVIA's revenue was up 2.5% compared to the same quarter last year. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.